

Christopher S King

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8665630/christopher-s-king-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

3,756
citations

15
h-index

61
g-index

65
ext. papers

4,882
ext. citations

4.4
avg, IF

5.28
L-index

#	Paper	IF	Citations
55	Impact of Noninvasive Respiratory Support in Patients With COVID-19 Requiring V-V ECMO.. <i>ASAIO Journal</i> , 2022 , 68, 171-177	3.6	0
54	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.. <i>Pulmonary Circulation</i> , 2022 , 12, e12055	2.7	0
53	Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021 , 38, e2021005	1.1	1
52	63: D-Dimer and Fibrinogen Magnitude and Hypercoagulability by Thromboelastography in Severe COVID-19. <i>Critical Care Medicine</i> , 2021 , 49, 33-33	1.4	
51	Association of D-dimer and Fibrinogen With Hypercoagulability in COVID-19 Requiring Extracorporeal Membrane Oxygenation. <i>Journal of Intensive Care Medicine</i> , 2021 , 36, 689-695	3.3	8
50	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. <i>Pulmonary Circulation</i> , 2021 , 11, 2045894021999960	2.7	2
49	Extracorporeal life support for cardiogenic shock during pregnancy and postpartum: a single center experience. <i>Perfusion (United Kingdom)</i> , 2021 , 2676591211004369	1.9	
48	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1803-1810	4.7	0
47	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211012366	2.7	0
46	Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
45	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1266-1274	35.1	11
44	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1267-1278	5.8	
43	Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. <i>Chest</i> , 2021 , 159, 1507-1516	5.3	5
42	High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. <i>Respiratory Care</i> , 2021 , 66, 909-919	2.1	37
41	Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021 , 15, 11795484211047065	2.4	2
40	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. <i>Respiratory Research</i> , 2021 , 22, 5	7.3	2
39	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, e545-e608	5.3	48

38	Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, 2247-2259	5.3	35
37	Lung Transplantation of COVID-19 Patients. <i>Chest</i> , 2021 ,	5.3	8
36	Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	6
35	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1601-1609	4.7	1
34	The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. <i>Chest</i> , 2020 , 158, 1651-1664	5.3	15
33	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2020 , 170, 106068	4.6	5
32	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. <i>PLoS ONE</i> , 2020 , 15, e0242651	3.7	33
31	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 191	3.5	1
30	HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. <i>Therapeutic Advances in Respiratory Disease</i> , 2020 , 14, 1753466620968496	4.9	3
29	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure 2020 , 15, e0242651		
28	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure 2020 , 15, e0242651		
27	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure 2020 , 15, e0242651		
26	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure 2020 , 15, e0242651		
25	Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. <i>Transplant Infectious Disease</i> , 2019 , 21, e13166	2.7	21
24	Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure. <i>Journal of Medical Cases</i> , 2019 , 10, 260-263	0.2	
23	Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities. <i>Respiratory Medicine</i> , 2019 , 273-297	0.2	2
22	Pulmonary hypertension due to interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2019 , 25, 459-467	3	12
21	Critical Care of the Adult Patient With Cystic Fibrosis. <i>Chest</i> , 2019 , 155, 202-214	5.3	14

20	A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation. <i>Chest</i> , 2018 , 153, e53-e56	5.3	5
19	A 70-Year-Old Woman Presenting With Diarrhea and In-hospital Cardiac Arrest. <i>Chest</i> , 2018 , 153, e5-e8	5.3	0
18	Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	4
17	Fungal thyroiditis in a lung transplant recipient. <i>BMJ Case Reports</i> , 2018 , 2018,	0.9	2
16	Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	11
15	Early postoperative management after lung transplantation: Results of an international survey. <i>Clinical Transplantation</i> , 2017 , 31, e12985	3.8	5
14	Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. <i>Chest</i> , 2017 , 152, 980-989	5.3	1
13	Cardiac Support: Emphasis on Venous Arterial ECMO. <i>Critical Care Clinics</i> , 2017 , 33, 777-794	4.5	10
12	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 72-84	35.1	97
11	Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. <i>Multidisciplinary Respiratory Medicine</i> , 2016 , 11, 40	3	14
10	Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016 , 47, 1445-51	13.6	33
9	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2016 , 149, 315-352	5.3	3090
8	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2015 , 21, 479-89	3	30
7	Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014 , 108, 1626-32	4.6	55
6	Management of right heart failure in the critically ill. <i>Critical Care Clinics</i> , 2014 , 30, 475-98	4.5	19
5	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 875-85	4.4	19
4	Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. <i>Chest</i> , 2013 , 143, 1106-1116	5.3	23
3	Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2013 , 19, 466-73	3	36

- | | | |
|---|---|---|
| 2 | Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. <i>Current Respiratory Care Reports</i> , 2012 , 1, 233-242 | 7 |
| 1 | Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastography in severe COVID-19 | 1 |